The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Following a +9.72% 3-day Advance, the price is estimated to grow further. Considering data from situations where LNAI advanced for three days, in 182 of 211 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
LNAI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on September 17, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on LNAI as a result. In 78 of 82 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LNAI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for LNAI entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 57 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-0.223) is normal, around the industry mean (2.973). P/E Ratio (-0.008) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (294.118) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 98 (best 1 - 100 worst), indicating slightly worse than average price growth. LNAI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LNAI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
XBIT saw its Momentum Indicator move below the 0 level on October 13, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 110 similar instances where the indicator turned negative. In 94 of the 110 cases, the stock moved further down in the following days. The odds of a decline are at 85%.
The Moving Average Convergence Divergence Histogram (MACD) for XBIT turned negative on October 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 56 similar instances when the indicator turned negative. In 43 of the 56 cases the stock turned lower in the days that followed. This puts the odds of success at 77%.
XBIT moved below its 50-day moving average on October 13, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where XBIT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
The Aroon Indicator for XBIT entered a downward trend on October 08, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +4.57% 3-day Advance, the price is estimated to grow further. Considering data from situations where XBIT advanced for three days, in 136 of 201 cases, the price rose further within the following month. The odds of a continued upward trend are 68%.
XBIT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron PE Growth Rating for this company is 27 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 73 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.468) is normal, around the industry mean (2.973). P/E Ratio (-1.331) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (5.015) settles around the average of (128.121) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 74 (best 1 - 100 worst), indicating slightly worse than average price growth. XBIT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. XBIT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
LNAI | XBIT | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 75 | 20 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 57 Fair valued | 73 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 100 | 97 | |
PRICE GROWTH RATING 1..100 | 98 | 74 | |
P/E GROWTH RATING 1..100 | 6 | 27 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
LNAI's Valuation (57) in the Financial Conglomerates industry is in the same range as XBIT (73) in the Biotechnology industry. This means that LNAI’s stock grew similarly to XBIT’s over the last 12 months.
LNAI's Profit vs Risk Rating (100) in the Financial Conglomerates industry is in the same range as XBIT (100) in the Biotechnology industry. This means that LNAI’s stock grew similarly to XBIT’s over the last 12 months.
XBIT's SMR Rating (97) in the Biotechnology industry is in the same range as LNAI (100) in the Financial Conglomerates industry. This means that XBIT’s stock grew similarly to LNAI’s over the last 12 months.
XBIT's Price Growth Rating (74) in the Biotechnology industry is in the same range as LNAI (98) in the Financial Conglomerates industry. This means that XBIT’s stock grew similarly to LNAI’s over the last 12 months.
LNAI's P/E Growth Rating (6) in the Financial Conglomerates industry is in the same range as XBIT (27) in the Biotechnology industry. This means that LNAI’s stock grew similarly to XBIT’s over the last 12 months.
| LNAI | XBIT | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 90% | 1 day ago 82% |
| Stochastic ODDS (%) | N/A | 1 day ago 78% |
| Momentum ODDS (%) | 4 days ago 90% | 1 day ago 85% |
| MACD ODDS (%) | N/A | 1 day ago 77% |
| TrendWeek ODDS (%) | 1 day ago 90% | 1 day ago 82% |
| TrendMonth ODDS (%) | 1 day ago 90% | 1 day ago 83% |
| Advances ODDS (%) | 2 days ago 86% | 14 days ago 68% |
| Declines ODDS (%) | 4 days ago 90% | 1 day ago 80% |
| BollingerBands ODDS (%) | 1 day ago 90% | 1 day ago 71% |
| Aroon ODDS (%) | 1 day ago 88% | 1 day ago 84% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
LNAI’s FA Score shows that 1 FA rating(s) are green while XBIT’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
LNAI’s TA Score shows that 3 TA indicator(s) are bullish while XBIT’s TA Score has 4 bullish TA indicator(s).
LNAI (@Biotechnology) experienced а -41.94% price change this week, while XBIT (@Biotechnology) price change was -8.80% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.10%. For the same industry, the average monthly price growth was -18.18%, and the average quarterly price growth was -15.20%.
LNAI is expected to report earnings on Nov 13, 2026.
XBIT is expected to report earnings on Nov 11, 2026.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
A.I.dvisor indicates that over the last year, LNAI has been closely correlated with CANF. These tickers have moved in lockstep 72% of the time. This A.I.-generated data suggests there is a high statistical probability that if LNAI jumps, then CANF could also see price increases.
| Ticker / NAME | Correlation To LNAI | 1D Price Change % | ||
|---|---|---|---|---|
| LNAI | 100% | -9.27% | ||
| CANF - LNAI | 72% Closely correlated | -3.15% | ||
| APVO - LNAI | 60% Loosely correlated | +0.62% | ||
| GNPX - LNAI | 56% Loosely correlated | -3.41% | ||
| ICU - LNAI | 55% Loosely correlated | -10.09% | ||
| MLEC - LNAI | 48% Loosely correlated | +1.51% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| MILN | 44.41 | 0.59 | +1.34% |
| Global X Millennial Consumer ETF (MILN) | |||
| USNZ | 49.71 | N/A | N/A |
| Xtrackers Net Zero Pathway Paris Aligned US Equity ETF (USNZ) | |||
| FNOV | 60.41 | -0.40 | -0.67% |
| FT Vest U.S. Equity Buffer ETF - November (FNOV) | |||
| CWY | 13.42 | -0.35 | -2.53% |
| GraniteShares YieldBOOST CRWV ETF (CWY) | |||
| GPT | 33.06 | -1.15 | -3.36% |
| Intelligent Alpha Atlas ETF (GPT) | |||